Sanofi welcomes new lung cancer listing for immune checkpoint inhibitor

Kasia Siwek, Sanofi's country medical head for Australia and NZ, said, “At Sanofi, we are proud of our ongoing work with both the Australian clinical community and the government to broaden access to LIBTAYO as a first-line treatment for eligible Australians diagnosed with metastatic NSCLC. …